AstraZeneca acquires France’s Amolyt Pharma for $1.05 billion
British-Swedish AstraZeneca has acquired Amolyt Pharma for $1.05 billion to gain access to Lyon, France-based company’s rare disease, late-stage pipeline.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
British-Swedish AstraZeneca has acquired Amolyt Pharma for $1.05 billion to gain access to Lyon, France-based company’s rare disease, late-stage pipeline.
Novo Nordisk’s end-stage trial for hypertension drug has failed to meet its primary goal and the Danish multinational has recognised an impairment loss.
HQ Team May 20, 2024: Vitamin D deficiency is associated with poor outcomes in cardiovascular diseases and chronic kidney disease (CKD) in patients with early-stage.
HQ Team March 6, 2024: Novo Nordisk’s diabetes drug Ozempic delayed the progression of kidney disease and cardiovascular and kidney death in 24%.
HQ Team October 16, 2023: Danish pharmaceutical company, Novo Nordisk, announced it was buying a hypertension drug, still in trials, from Singapore-based KBP.